Leerink Swann Starts Roka Bioscience (ROKA) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
BofA/Merrill Lynch Starts Roka Bioscience (ROKA) at Buy
August 11, 2014 10:55 AM EDTBofA/Merrill Lynch initiates coverage on Roka Bioscience (NASDAQ: ROKA) with a Buy rating and a price target of $14.00.
Analyst Derik de Bruin is bullish on the company's platform and prospects and he sees upside potential from expanding into new... More
Roka Bioscience (ROKA) Reports Narrower Q2 Loss
August 11, 2014 9:55 AM EDTRoka Bioscience (NASDAQ: ROKA) reported Q2 EPS of ($11.28), versus ($15.96) reported last year. Revenue for the quarter came in at $1.4 million, versus $671 thousand reported last year.
For earnings history and earnings-related data on Roka Bioscience (ROKA) click here.
... More